Fig. 3

Efficacy and safety profiles of the triplet regimen in patients grouped by CD8 status. A Profile of the FUTURE-C-Plus trial. B Infiltration of CD8⁺ cells based on tumor source (primary or metastatic) and anatomical location. C Best percentage change from baseline in the target lesion in patients grouped by CD8 status. D Frequency of adverse events in patients grouped by CD8 status. All patients (n = 48) were included in the safety analysis. One case of ALT/AST increase was defined as potentially immune-related. $ Hematological toxicity; # potential immune-related toxicity. TSH, thyroid-stimulating hormone; ALT, alanine aminotransferase; AST, aspartate aminotransferase